Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 8, 2023
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) invites investors to its live presentation at the Emerging Growth Conference on February 8, 2023. The interactive session will provide insights on the company's strategic plans, drug pipeline, and upcoming 1-for-1500 reverse stock split effective March 6, 2023. CEO Dr. David Koos will address shareholder questions during the event.
Regen BioPharma is focused on advancing therapies for cancer and autoimmune disorders through pre-clinical and Phase I/II clinical trials. The conference presentation is scheduled from 2:20 - 2:50 PM Eastern Time. An archived webcast will be available post-event.
- None.
- None.
This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO, Dr.
"We plan to use this time to update our stakeholders on our corporate strategic plans, drug pipeline, drug development strategy and answer shareholder questions," says Dr.
If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com.
About the
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.
The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of individual and institutional investors, as well as investment advisors and analysts.
About
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Chairman & Chief Executive Officer
david.koos@regenbiopharmainc.com
+1-619-722-5505 Phone
+1-619-330-2328 Fax
Follow us on Twitter for future updates: https://twitter.com/TheRegenBio
View original content:https://www.prnewswire.com/news-releases/regen-biopharma-inc-to-present-at-the-emerging-growth-conference-on-february-8-2023-301741123.html
SOURCE
FAQ
What is the date of Regen BioPharma's presentation at the Emerging Growth Conference?
What will be discussed in the presentation by Dr. David Koos?
What is the reverse stock split effect on Regen BioPharma's stocks?
How can I attend the Regen BioPharma presentation?
What is the stock symbol for Regen BioPharma?